Virological efficacy of abacavir: Systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3169-3180

  Cruciani, Mario ^a   Mengoli, Carlo ^b   Malena, Marina ^a   Serpelloni, Giovanni ^a   Parisi, Saverio G ^b   Moyle, Graeme ^c   Bosco, Oliviero ^a  

^a Center of Preventive Medicine and HIV Outpatient Clinic   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiviral; Meta regression; Tenofovir

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE;

ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; ANALOGS AND DERIVATIVES; HIV INFECTIONS;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HUMANS; LAMIVUDINE; ORGANOPHOSPHONATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84921751896     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku279     Document Type: Article

References (61)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf (10 June 2014, date last accessed).
2. European AIDS Clinical Society. Guidelines. Clinical Management and Treatment of HIV Infected Adults in Europe. 7.0, October 2013. http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf (13 June 2014, date last accessed).
3. Ford N, Shubber Z, Hill A et al. Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One 2013; 8: e79981.
4. Sax PE, Tierney C, Collier AC et al. Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230-40.
5. Smith KY, Patel P, Fine D et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23: 1547-56.
6. Pappa K, Hernandez J, Ha B et al. Abacavir/lamivudine shows robust virologic responses in ART-naive patients for baseline (BL) viral loads of.100,000 c/mL and ,100,000 c/mL by endpoint used in ACTG5202. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract THAB0304.
7. Cruciani M, Zanichelli V, Serpelloni G et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25: 1993-2004.
8. Ding X, Andraca-Carrera E, Cooper C et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61: 441-7.
9. US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. June 2013. http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM355128.pdf (13 June 2014, date last accessed).
10. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org (13 June 2014, date last accessed).
11. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
12. Higgins J, Thompson S, Deeks J et al. Measuring inconsistency in meta-analyses. BMJ 2003; 32: 557-60.
13. Sterne J, Jüni P, Moher D. Investigating and dealing with bias in systematic reviews. In: Abstracts of the 16th Cochrane Colloquium 'Evidence in the Era of Globalisation', Freiberg, Germany, October 2008. Volume 6, Zeitschrift fur Evidenz, Fortbildung und Qualitat in Gesundheitwesen. Supplement. Elsevier, 2008.
14. Clumeck N, Goebel F, RozenbaumWet al. Simplification with abacavirbased triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-26.
15. Staszewski S, Keiser P, Montaner J et al. Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285: 1155-63.
16. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
17. Katlama C, Fenske S, Gazzard et al. TRIZAL study: switching fromsuccessful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4: 79-86.
18. Maggiolo F, Ripamonti D, Ravasio L et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003; 37: 41-9.
19. Martínez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46.
20. Matheron S, Descamps D, Boué F et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003; 8: 163-71.
21. Vibhagool A, Cahn P, Schechter M et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 2004; 20: 1103-14.
22. Bonjoch A, Paredes R, Galvez J et al. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr 2005; 39: 313-6.
23. Keiser PH, Sension MG, DeJesus E et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005; 5: 2.
24. Orkin C, Stebbing J, Nelson M et al. A randomized study comparing a three-and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 2005; 55: 246-51.
25. Kumar PN, Rodriguez-French A, Thompson MA et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006; 7: 85-98.
26. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
27. Martínez E, Arnaiz JA, Podzamczer D et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS 2007; 21: 367-9.
28. Kumar PN, Salvato P, Lamarca A et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twicedaily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther 2009; 6: 3.
29. Martin A, Bloch M, Amin J et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49: 1591-601.
30. Martínez E, Arranz JA, Podzamczer D et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51: 290-7.
31. Amin J, De Lazzari E, Emery S et al. Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in treatment experienced, virologically suppressed adults with HIV infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal. J AIDS Clinic Res 2010; 1: 103.
32. Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
33. Post FA, Moyle GJ, Stellbrink HJ et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviralnaive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55: 49-57.
34. Raffi F, Rachlis A, Stellbrink HJ et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
35. Raffi F, Jaeger H, Quiros-Roldan E et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, noninferiority trial. Lancet Infect Dis 2013; 13: 927-35.
36. Nishijima T, Takano M, Ishisaka M et al. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med 2013; 52: 735-44.
37. Moyle GJ, Stellbrink HJ, Compston J et al. 96-week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviralnaive, HIV-1-infected adults: ASSERT study. Antivir Ther 2013; 18: 905-13.
38. Clotet B, Feinberg J, van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222-31.
39. Sax P, Tierney C, Collier A et al. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine than tenofovir/emtricitabine as part of combination therapy in treatment-naïve subjects with screening HIV RNA 100,000 c/mL. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract THAB0303
40. GSK repository data on file.
41. Sax PE, Tierney C, Collier AC et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204: 1191-201.
42. The DAD Study Group. Class of antiretroviral drugs and the risk ofmyocardial infarction. N Engl J Med 2007; 356: 1723-35.
43. Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
44. Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.
45. The SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-24.
46. Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228-38.
47. Bedimo RJ,Westfall AO, Drechsler H et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53: 84-91.
48. Ribaudo HJ, Benson CA, Zheng Yet al. No risk ofmyocardial infarction associated with initial antiretroviral treatment containing abacavir: short and longterm results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52: 929-40.
49. Brothers CH, Hernandez JE, Cutrell AG et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKlinesponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51: 20-8.
50. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009; 50: 54-64.
51. Francisci D, Giannini S, Baldelli F et al. HIV type 1 infection, and not shortterm HAART, induces endothelial dysfunction. AIDS 2009; 23: 589-96.
52. Hsue PY, Hunt PW, Wu Y et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23: 2021-7.
53. Martínez E, Larrousse M, Podzamczer D et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24: F1-9.
54. Jong E, Meijers JC, van Gorp EC et al. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther 2010; 7: 9.
55. Martin A, Amin J, Cooper DA et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24: 2657-63.
56. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
57. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. WHO, November 2009. http://www.who.int/hiv/pub/arv/rapid_advice:art.pdf (3 May 2014, date last accessed).
58. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008; 9: 207-14.
59. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Homvariant. Proc Natl Acad Sci USA 2004; 101: 4180-5.
60. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
61. Tan DH, Chan K, Raboud J et al. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr 2011; 58: 38-46.